Rapid Micro Biosystems, Inc.
We are an innovative life sciences technology company providing automated microbial quality control (MQC) to facilitate the efficient manufacturing as well as the fast and safe release of healthcare products such as biologics, vaccines, cell and gene therapies and sterile injectables. Our flagship Growth Direct platform automates and modernizes the antiquated manual microbial quality control or MQC testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. Our customer base includes over half of the top 20 pharmaceutical companies as measured by revenue and 30% of globally approved cell and gene therapies.
(Note: Rapid Micro Biosystems, Inc. upsized its IPO at pricing on July 14, 2021, to 7.92 million shares, up from 6.6 million shares in the prospectus, at $20 – the top of its $18-to-$20 price range – to raise $158.4 million.)
|Industry:||LABORATORY ANALYTICAL INSTRUMENTS|
|Address||1001 Pawtucket Boulevard West, Suite 280 Lowell, Massachusetts 01854|
|View Prospectus:||Rapid Micro Biosystems, Inc.|
|Revenues||$14.83 mil (last 12 months)|
|Net Income||$-51.17 mil (last 12 months)|
|Price range||$20.00 - $20.00|
|Est. $ Volume||$158.4 mil|
|Manager / Joint Managers||J.P. Morgan/ Morgan Stanley/ Cowen/ Stifel|
|Expected To Trade:||7/15/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|